Amgen (AMGN) Offering Possible 17.37% Return Over the Next 13 Calendar Days

Amgen's most recent trend suggests a bullish bias. One trading opportunity on Amgen is a Bull Put Spread using a strike $170.00 short put and a strike $165.00 long put offers a potential 17.37% return on risk over the next 13 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $170.00 by expiration. The full premium credit of $0.74 would be kept by the premium seller. The risk of $4.26 would be incurred if the stock dropped below the $165.00 long put strike price.

The 5-day moving average is moving up which suggests that the short-term momentum for Amgen is bullish and the probability of a rise in share price is higher if the stock starts trending.

The 20-day moving average is moving up which suggests that the medium-term momentum for Amgen is bullish.

The RSI indicator is at 61.54 level which suggests that the stock is neither overbought nor oversold at this time.

To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here

LATEST NEWS for Amgen

Is Amgen, Inc. (AMGN) A Good Stock To Buy?
Thu, 06 Jun 2019 21:59:54 +0000
The elite funds run by legendary investors such as David Tepper and Dan Loeb make hundreds of millions of dollars for themselves and their investors by spending enormous resources doing research on small cap stocks that big investment banks don't follow. Because of their pay structures, they have strong incentives to do the research necessary […]

Amgen (AMGN) Stock Sinks As Market Gains: What You Should Know
Thu, 06 Jun 2019 21:50:09 +0000
In the latest trading session, Amgen (AMGN) closed at $174.45, marking a -0.06% move from the previous day.

5 Healthcare Stocks to Pick Up From the Wreckage
Thu, 06 Jun 2019 19:13:05 +0000
Once loved, healthcare stocks are quickly becoming some of the most hated stocks on the planet. It's easy to understand why. Rising drug and procedure costs have made many healthcare stocks targets for various political pundits and presidential candidates. The growing calls for Medicare-For-All and/or socialized medicine has the potential to hit many healthcare firms right in the pocket. When coupled with the general market sell-off, the fast-moving healthcare sector has been a real downer.But that has only made the sector prime for bargain shopping.Even with calls for increased regulation, the healthcare sector still has great long-term potential. Thanks to rising global demand, aging populations as well as new high-tech and high-margined therapies, there are lots of levers for the sector to pull in order to keep the profits coming. And while some healthcare stocks will be hit hard in the regulation wave (like insurance and pharmacy benefit managers), many will be just fine. This could make the recent declines a tantalizing buy-in point for portfolios.InvestorPlace – Stock Market News, Stock Advice & Trading Tips * 10 Stocks to Buy That Could Be Takeover Targets With the long-term in mind, here are five healthcare stocks that are worth picking up from the wreckage. Abiomed (ABMD)Source: Shutterstock There's a good chance that you've never heard of Abiomed (NASDAQ:ABMD). The firm was only added to the S&P 500 about a year ago. But in that time, it has grown immensely in terms of fundamentals and share price.ABMD produces the Impella, which is the world's smallest heart pump. The device is minimally invasive. That's a key selling point for doctors. Open-heart surgery is risky to begin with, but especially so for patients who have suffered some sort of major cardiovascular event. Impella eliminates many of the risks. Meanwhile, the device can be configured in a variety of applications. Because of this, the Impella is quickly becoming the standard of care for doctors in cardiac surgery.As a result, sales of the device continue to surge. For full-year 2018 results, ABMD managed to see a 30% jump in sales and nearly 43% increase in profits based on continued demand for the game-changing device. And yet, the runway is still long for the firm. There's plenty of market share in the U.S. to gain from older heart pump devices and global demand is still in its infancy. Meanwhile, the firm continues to attract plenty of buyout/M&A buzz and would be a wonderful tuck-in deal for many larger device stocks.However, shares of ABMD are about 35% below their all-time highs from last year. And it isn't cheap from a price-to-earnings perspective either. ABMD is a classic growth stock, but the recent dip makes for an interesting buy-in for those willing to hold it over the long term. Teledoc (TDOC)Source: MayApps207 via WikiMedia Saving money and reducing costs is exactly what any pending regulation in the sector will be all about. That's great news for Teledoc (NASDAQ:TDOC). The firm is the largest player in the growing telemedicine field. Here, patients can fire-up their tablets, PCs or smartphones and speak to a physician in real time, get a diagnosis and even send a prescription to their local pharmacy.Health insurers, benefit managers, employers and consumers seem keen on the idea. More employers are adding the service to their benefits package, with more than 40% of the Fortune 500 offering it in their benefits.This has allowed TDOC to experience some very fast growth over the last few years. between 2016 and what its estimated to pull in this year, Teledoc has seen a staggering 64% compound annual growth rate in terms of revenues. Meanwhile, the firm is finally starting to turn those revenues into meaningful and growing profits.And the growth could continue. TDOC has moved into the mental health arena and has been smartly buying smaller rivals to add instant market share. Meanwhile, more companies continue to see the benefits of adding the platform to their Human Resources package. * The 10 Best Stocks for 2019 — So Far All in all, TDOC is a high growth healthcare stock that is now trading much lower than expected. Amgen (AMGN)Source: Shutterstock As one of biotech and healthcare's elder statesmen, Amgen (NASDAQ:AMGN) has been hit hard over the last year on drug pricing news. Key blockbusters like Enbrel and Neulasta are two of the most prescribed drugs in their categories and mint cash for AMGN. Those blockbusters, as well as others, such as Repatha, blood-cancer drug Kyprolis and bone-density drug Prolia, are the reasons why Amgen has become a dividend and buyback stalwart. Their high prices are also the reason why AMGN is in the crosshairs of lawmakers.Despite that and the drop in AMGN stock, investors may want to consider the firm.For one thing, Amgen continues to dive head first into more advanced cancer and gene therapy drugs. These specialized drugs are naturally higher cost. There's very little that regulation can do for them. With data from Amgen's new cancer therapies crushing the trial, there's a good chance that the firm will have another blockbuster in its arsenal. And we can't forget about its massive pipeline either.In the end, AMGN will be pretty immune from the effects of regulation and will continue to rack up massive cash flows from specialized drugs. That should help pad its now 3.32% dividend for years to come. Stryker Corporation (SYK)Source: Shutterstock Artificial knees, hospital beds and even specialized bone cement … medical device company Stryker (NYSE:SYK) has it all. And that could make it a top healthcare stock contender to snag-up in the recent sector wreckage. SYK has its hands in many pots and that will allow it to handle anything the government throws at it.This is evident by its continued surge in sales and revenues. Last quarter, SYK managed to see a big 8.5% jump in net sales. The key was that divisions featuring more high-tech devices and products, such as orthopedics and neurotechnology, saw big double-digit sales gains. The medical device firm has continued to boost these divisions with smart M&A as well as new innovative internal product launches. That's a good thing as these higher-tech areas are seen as being more insulated to regulation. For Stryker and its shareholders, this could be gold for the long haul.Speaking of that gold, SYK has been sharing the wealth with investors as well. The firm's latest dividend represents a big 11% increase. At the same time, Stryker has been a buyback champ as well — reducing its share count by about $1 billion last year. * 10 Heavily Shorted Stocks to Sell — Because the Bears Are Right With a forward P/E of 22, Stryker isn't super cheap, but considering its growth estimates and potential to keep the good times going in the face of regulation, that could seem like a bargain. Bristol-Myers Squibb (BMY)Source: A 4 via Flickr It's not surprising that old-school pharma has been hit hard in recent weeks. But there's nothing particularly old school about Bristol-Myers Squibb (NYSE:BMY). That's because BMY has quickly become the anti-cancer and advanced drug machine.BMY already had top blockbuster cancer-fighter Opdivo, which pulls in more than $2 billion in quarterly revenues for the firm. But thanks to its recent $74 billion out of Celgene (NASDAQ:CELG), Bristol-Meyers will have one of the richest oncology portfolios around. This includes blockbusters Yervoy, Revlimid and Pomalyst which will all now be under its umbrella. This doesn't even include CELG's rich pipeline nor BMY's own advanced cancer-fighting drugs under development.As we said before, specialized cancer drugs are big revenues drivers and given just how advanced they are, the government may have little ability to regulate them. This should help drive revenues and cash flows at Bristol-Meyer's for years to come. And yes, patent expiration for Revlimid is coming down the pike. But under BMY's vast portfolio of drugs, that expiration means less than when it was CELG's chief revenue driver.Yet, BMY trades at a real discount to other big healthcare stocks. For investors, the top and future cancer fighter offers a great long-term play at cheap prices.As of this writing, Aaron Levitt was long AMGN and ABMD. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * The 4 FANG Stocks Won't Be Bitten By Regulation Threats * 10 Stocks to Buy That Could Be Takeover Targets * 4 Big Bank Stocks Rebounding Compare Brokers The post 5 Healthcare Stocks to Pick Up From the Wreckage appeared first on InvestorPlace.

Should We Be Delighted With Amgen Inc.'s (NASDAQ:AMGN) ROE Of 75%?
Thu, 06 Jun 2019 18:30:29 +0000
While some investors are already well versed in financial metrics (hat tip), this article is for those who would like…

Lilly's Emgality Gets FDA Approval for Cluster Headache
Thu, 06 Jun 2019 13:22:01 +0000
Lilly's (LLY) CGRP antibody, Emgality, becomes the first and only medicine approved to treat episodic cluster headache in adults.

Related Posts

 

MarketTamer is not an investment advisor and is not registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authority. Further, owners, employees, agents or representatives of MarketTamer are not acting as investment advisors and might not be registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory.


This company makes no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended in this email, and makes no representations or warranties concerning said company or entity’s compliance with applicable laws and regulations, including, but not limited to, regulations promulgated by the SEC or the CFTC. The sender of this email may receive a portion of the proceeds from the sale of any products or services offered by a company or entity mentioned or recommended in this email. The recipient of this email assumes responsibility for conducting its own due diligence on the aforementioned company or entity and assumes full responsibility, and releases the sender from liability, for any purchase or order made from any company or entity mentioned or recommended in this email.


The content on any of MarketTamer websites, products or communication is for educational purposes only. Nothing in its products, services, or communications shall be construed as a solicitation and/or recommendation to buy or sell a security. Trading stocks, options and other securities involves risk. The risk of loss in trading securities can be substantial. The risk involved with trading stocks, options and other securities is not suitable for all investors. Prior to buying or selling an option, an investor must evaluate his/her own personal financial situation and consider all relevant risk factors. See: Characteristics and Risks of Standardized Options. The www.MarketTamer.com educational training program and software services are provided to improve financial understanding.


The information presented in this site is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. Nothing in our research constitutes legal, accounting or tax advice or individually tailored investment advice. Our research is prepared for general circulation and has been prepared without regard to the individual financial circumstances and objectives of persons who receive or obtain access to it. Our research is based on sources that we believe to be reliable. However, we do not make any representation or warranty, expressed or implied, as to the accuracy of our research, the completeness, or correctness or make any guarantee or other promise as to any results that may be obtained from using our research. To the maximum extent permitted by law, neither we, any of our affiliates, nor any other person, shall have any liability whatsoever to any person for any loss or expense, whether direct, indirect, consequential, incidental or otherwise, arising from or relating in any way to any use of or reliance on our research or the information contained therein. Some discussions contain forward looking statements which are based on current expectations and differences can be expected. All of our research, including the estimates, opinions and information contained therein, reflects our judgment as of the publication or other dissemination date of the research and is subject to change without notice. Further, we expressly disclaim any responsibility to update such research. Investing involves substantial risk. Past performance is not a guarantee of future results, and a loss of original capital may occur. No one receiving or accessing our research should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing any applicable prospectuses, press releases, reports and other public filings of the issuer of any securities being considered. None of the information presented should be construed as an offer to sell or buy any particular security. As always, use your best judgment when investing.